<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Polyethylene glycol 3350: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Polyethylene glycol 3350: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Polyethylene glycol 3350: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11568" href="/d/html/11568.html" rel="external">see "Polyethylene glycol 3350: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13070" href="/d/html/13070.html" rel="external">see "Polyethylene glycol 3350: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2295346"><span class="drugH1">Brand Names: US</span>
<ul>
<li>FT ClearLax [OTC];</li>
<li>GaviLAX [OTC];</li>
<li>Gialax;</li>
<li>GlycoLax [OTC];</li>
<li>HealthyLax [OTC];</li>
<li>MiraLax [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F2295350"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Laxative, Osmotic</li></ul></div>
<div class="block doa drugH1Div" id="F2295373"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa734f35-4c17-48c8-bc08-884533bedae6">Bowel preparation before colonoscopy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bowel preparation before colonoscopy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">MiraLAX: <b>Oral:</b> 238 g (8.3 oz bottle) or 255 g (8.9 oz bottle [generic]) mixed in ~1,900 mL (64 ounces) of Gatorade® until dissolved (lemon-lime is typically used; do not use red). Administered as either the split-dose regimen or the evening-only regimen; both regimens are given with bisacodyl delayed-release oral tablets prior to the MiraLAX solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22711499','lexi-content-ref-32377915','lexi-content-ref-22565162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22711499','lexi-content-ref-32377915','lexi-content-ref-22565162'])">Ref</a></span>). <b>Note:</b> Timing of doses depends on when the procedure is scheduled and varies by institution preference.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<i>Split-dose (</i>
<i>2-day regimen) (preferred method due to improvement in adenoma detection rates) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22732876','lexi-content-ref-30865011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22732876','lexi-content-ref-30865011'])">Ref</a></span>):</i></i></p>
<p style="text-indent:-2em;margin-left:8em;">Dose 1: Evening before colonoscopy: <b>Oral:</b> 240 mL (8 oz) every 10 minutes for 4 doses until 960 mL (32 oz) is consumed.</p>
<p style="text-indent:-2em;margin-left:8em;">Dose 2: On the morning of the colonoscopy (typically given 5 hours prior to procedure): <b>Oral:</b> 240 mL (8 oz) every 10 minutes for 4 doses until 960 mL (32 ounces) is consumed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Evening-only dose (1-day regimen) (alternate method):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Dose 1: Evening before colonoscopy: <b>Oral:</b> 240 mL (8 oz) every 10 minutes until ~1900 (64 oz) (entire contents of container) is consumed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22565162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22565162'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f7d0405-0daa-4433-ac8b-56835ffe8655">Chronic idiopathic constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic idiopathic constipation (off-label use): Oral: </b>17 g dissolved in 240 mL (8 oz) of liquid once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37204227','lexi-content-ref-17403074']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37204227','lexi-content-ref-17403074'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="387e55f0-7a7e-4f50-ab02-5492aebb64f2">Constipation, occasional</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constipation, occasional:</b>
<b>Oral:</b> 17 g (~1 heaping tablespoon) dissolved in 120 to 240 mL (4 to 8 ounces) of beverage, once daily; do not use for &gt;1 to 2 weeks (product specific) unless directed by health care provider. In a clinical trial, 34 g once daily was shown to be effective, but with increased adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DiPalma.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DiPalma.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d9895d84-f23d-4ab8-b478-fe854563cc86">Irritable bowel syndrome with constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Irritable bowel syndrome with constipation (adjunct) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for patients with persistent constipation despite soluble fiber or who are intolerant to other laxatives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23835436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23835436'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 17 g dissolved in 120 to 240 mL (4 to 8 ounces) of liquid, once daily as needed; may increase to a maximum dose of 34 g per day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23835436','lexi-content-ref-17984738','lexi-content-ref-17573794','lexi-content-ref-Wald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23835436','lexi-content-ref-17984738','lexi-content-ref-17573794','lexi-content-ref-Wald.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990683"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed: No supplemental dose or dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed: No dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (systemic absorption limited) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987986"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F2482702"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F7814689"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13070" href="/d/html/13070.html" rel="external">see "Polyethylene glycol 3350: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> 17 g=1 capful=1 heaping tablespoonful (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-MiraLAX.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-MiraLAX.2'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1d91e5c-6080-4c3c-9c18-cb1b53ab05d6">Bowel preparation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bowel preparation:</b> Limited data available: Children &gt;2 years and Adolescents: Oral: 1.5 g/kg/day for 4 days; in the trial, daily dose was administered in 2 to 3 divided doses; maximum daily dose: 100 g/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15001943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15001943'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5cf5683d-351d-423d-a054-afa1e6798e5c">Constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constipation: </b>Limited data available: Infants, Children, and Adolescents: Oral: Initial: 0.4 to 0.8 g/kg/day once daily or in divided doses; doses should be individualized to achieve desired effect; usual maintenance dose: 0.2 to 1.5 g/kg/day. Usual maximum daily dose: 17 g/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23204909','lexi-content-ref-15572895','lexi-content-ref-24345831','lexi-content-ref-11562624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23204909','lexi-content-ref-15572895','lexi-content-ref-24345831','lexi-content-ref-11562624'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2633c46a-7e2a-45d5-8aa4-184818b49182">Fecal impaction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fecal impaction:</b> Limited data available: Children and Adolescents: Oral: 1 to 1.5 g/kg/day once daily for 3 to 6 consecutive days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24345831','lexi-content-ref-12219064']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24345831','lexi-content-ref-12219064'])">Ref</a></span>); maximum daily dose: 100 g/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12219064']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12219064'])">Ref</a></span>); following disimpaction, maintenance dose of 0.4 to 1 g/kg/day should be continued for ≥2 months followed by gradual decrease of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23204909','lexi-content-ref-24345831','lexi-content-ref-11562624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23204909','lexi-content-ref-24345831','lexi-content-ref-11562624'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51153901"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51153902"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F2295361"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal signs and symptoms (including abdominal cramps, abdominal distention, abdominal pain, bloating, diarrhea, dyspepsia, eructation, flatulence, frequent bowel movements, loose stools, nausea, rectal hemorrhage, stomach discomfort) (DiPalma 2007a, DiPalma 2007b)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (Lee 2015), anaphylaxis (Lee 2016), hypersensitivity reaction (Sari Gökay 2018), type I hypersensitivity reaction (Stone 2019)</p></div>
<div class="block coi drugH1Div" id="F2295357"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to polyethylene glycol or any component of the formulation; known or suspected bowel obstruction</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use if you have renal disease unless advised by a health care provider</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Relaxa: Use in children &lt;18 years of age unless advised by a physician</p></div>
<div class="block war drugH1Div" id="F2295358"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Prolonged, frequent, or excessive use may lead to electrolyte imbalance.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Do not use if you are hypersensitive to polyethylene glycol. If an allergic reaction develops (eg, rash, swelling, difficulty breathing), discontinue use immediately and seek medical care.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concern:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bowel obstruction: Evaluate patients with symptoms of bowel obstruction, appendicitis, or inflamed bowel (nausea, vomiting, abdominal pain or distension) prior to use; use is contraindicated in patients with known or suspected bowel obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: If severe diarrhea occurs, discontinue use. When used for bowel preparation for colonoscopy (off-label use), oral medications should not be administered within 1 hour of start of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Do not combine with starch-based thickeners; choking and potential aspiration may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of therapy: Do not use for longer than 1 to 2 weeks (product specific); 2 to 4 days may be required to produce bowel movement.</p>
<p style="text-indent:-2em;margin-left:4em;">• OTC labeling: When used for self-medication, patients should consult health care provider prior to use if they have nausea, vomiting, or abdominal pain, irritable bowel syndrome, or a sudden change in bowel habits for &gt;2 weeks. Patients should be instructed to discontinue use and consult health care provider if they have severe diarrhea, rectal bleeding, if abdominal pain, bloating, cramping, or nausea gets worse, or if need to use for &gt;1 week.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878700"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">The effects of long-term use or large doses of polyethylene glycol in children are unknown. The FDA has received reports of metabolic acidosis (with and without anion gap) and neuropsychiatric events in children taking polyethylene glycol; however, direct causality with the drug has not been established. Neuropsychiatric adverse events reported may include seizures, tremors, tics, headache, anxiety, lethargy, sedation, aggression, rages, obsessive-compulsive behaviors (including repetitive chewing and sucking), paranoia and mood swings. Studies are underway to define the metabolic processes and pathways polyethylene glycol (and any metabolites) in pediatric patients and to determine gastrointestinal absorption properties if any (FDA 2013). As of 2014, the FDA decided no action was necessary based upon available data (FDA 2014). Monitor pediatric patients closely for signs of metabolic acidosis or neuropsychiatric changes. </p></div>
<div class="block foc drugH1Div" id="F2295374"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gialax:  [contains aspartame, fd&amp;c yellow #5 (tartrazine), polyethylene glycol (interact starch)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HealthyLax: 17 g/dose (14 ea, 30 ea, 100 ea) [contains polyethylene glycol (interact starch)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">MiraLax: 17 g/dose (1 ea, 10 ea [DSC], 12 ea, 24 ea [DSC]) [contains polyethylene glycol (interact starch)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 17 g/dose (1 ea, 14 ea, 30 ea, 100 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Powder, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT ClearLax: 17 g/dose (119 g) [grit free, sugar free; contains polyethylene glycol (interact starch)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT ClearLax: 17 g/dose (238 g, 510 g) [sugar free; contains polyethylene glycol (interact starch)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GaviLAX: 17 g/dose (238 g, 510 g) [contains polyethylene glycol (interact starch)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GlycoLax: 17 g/dose (119 g [DSC], 255 g, 527 g) [contains polyethylene glycol (interact starch)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">MiraLax: 17 g/dose (1 ea, 119 g [DSC], 238 g, 510 g, 765 g [DSC]) [contains polyethylene glycol (interact starch)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 17 g/dose (119 g, 238 g, 255 g [DSC], 510 g, 527 g [DSC], 850 g)</p></div>
<div class="block geq drugH1Div" id="F2295348"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F54335574"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (HealthyLax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17 g (per each): $1.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (MiraLax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17 g (per each): $1.73</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Polyethylene Glycol 3350 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17 g (per each): $0.80 - $2.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (GlycoLax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17GM/SCOOP (per gram): $0.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (MiraLax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17GM/SCOOP (per gram): $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Powder</b> (Polyethylene Glycol 3350 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17GM/SCOOP (per gram): $0.02 - $0.04</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F7814690"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Constipation, occasional: Stir powder in 120 to 240 mL (4 to 8 ounces) of water, juice, soda, coffee, or tea (do not combine with starch-based thickeners) until dissolved and administer immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Bowel preparation for colonoscopy (off-label use): After mixing MiraLAX powder in Gatorade® (do not combine with starch-based thickeners), may chill in the refrigerator to increase palatability. Administer bisacodyl delayed-release tablets prior to polyethylene glycol administration. Administer using the split-dose (2-day regimen) or the evening-only dose (1-day regimen) prior to colonoscopy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22711499','lexi-content-ref-32377915','lexi-content-ref-22565162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22711499','lexi-content-ref-32377915','lexi-content-ref-22565162'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614187"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Stir powder in 120 to 240 mL (4 to 8 ounces) of water, juice, soda, coffee, or tea until dissolved and administer.</p></div>
<div class="block use drugH1Div" id="F2295351"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Constipation, occasional:</b> Treatment of occasional constipation</p></div>
<div class="block off-label drugH1Div" id="F25744662"><span class="drugH1">Use: Off-Label: Adult</span><p>Bowel preparation before colonoscopy; Chronic idiopathic constipation; Irritable bowel syndrome with constipation</p></div>
<div class="block mst drugH1Div" id="F2295345"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MiraLax may be confused with Mirapex</p>
<p style="text-indent:-2em;margin-left:4em;">Polyethylene glycol 3350 may be confused with polyethylene glycol electrolyte solution, propylene glycol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MiraLax may be confused with Murelax brand name for oxazepam [Australia]</p>
<p style="text-indent:-2em;margin-left:4em;">Polyethylene glycol 3350 may be confused with polyethylene glycol 4000 [international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299899"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222409"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Laxatives may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Polyethylene Glycol 3350 may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F2295354"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Polyethylene glycol (PEG) has minimal systemic absorption and would be unlikely to cause fetal malformations. Treatment of constipation in pregnant women is similar to that of nonpregnant patients and medications may be used when diet and lifestyle modifications are not effective. Polyethylene glycol may be used when an osmotic laxative is needed (Gomes 2018; Shin 2015).</p></div>
<div class="block pha drugH1Div" id="F2295368"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">An osmotic agent, polyethylene glycol 3350 causes water retention in the stool; increases stool frequency.</p></div>
<div class="block phk drugH1Div" id="F2295370"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: 24 to 96 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Minimal (&lt;0.28%; Pelham, 2008)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (93%); urine (0.2%) (Pelham, 2008)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58203796"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lagolax | Miralax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Agarol pur | Lax 3350 | Laxuave balance | Lumencol | Lumencol 2F | Peg 3350 richet | Tractolax</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Herron ClearLax | Laxettes activ8 | Vivalax | Your pharmacy clear laxative</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Transisoft</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Peg-lax</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Lax 3350</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Crisolax | Evalax | Farmalax 3350 | Freelax | Lasspeg | Pedialab | Peg 3350 | Polietilenglicol | Polietilenglicol 3350</span>;</li>
<li>
<span class="countryCode">(CR)</span> <span class="country">Costa Rica</span><span class="countrySeparator">: </span><span class="drugName">Magic lax</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bellymed abfur</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Neolax | Peg | Peg 3350</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Microlax Macrogol | Transipeglib</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Laxaclear | Transisoft</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Effecol 3350 | Miralax</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Endogol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Daylax | Pedilax</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Normalax</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cipeg | H peg | Pegmini | Pegmove | Pegred</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Agpeg | Dicopeg</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dulcolax Balance | Mirax</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Confortlax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Confortlax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Koilosell</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bellymed</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Evalax | Glycolax</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Surelax</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dicopeg junior</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dulcolax Balance | Gavilax | Gialax | Glycolax | Healthylax | Miralax | Peg 3350 | Peg 3350 Grx | Peg3350 | Polyethylene glycol | Polyethylene glycol 3350 | Polyethylene Glycol 3350 Laxative</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Barex unipeg | Corrilax | Transipeg</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Transipeg</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Pegdin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Polilax</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Evalax | Pasolax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37204227">
<a name="37204227"></a>Chang L, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation. <i>Am J Gastroenterol.</i> 2023;118(6):936-954. doi:10.14309/ajg.0000000000002227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/37204227/pubmed" id="37204227" target="_blank">37204227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35738724">
<a name="35738724"></a>Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. <i>Gastroenterology</i>. 2022;163(1):118-136. doi:10.1053/j.gastro.2022.04.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/35738724/pubmed" id="35738724" target="_blank">35738724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23835436">
<a name="23835436"></a>Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. <i>Am J Gastroenterol</i>. 2013;108(9):1508-1515. doi:10.1038/ajg.2013.197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/23835436/pubmed" id="23835436" target="_blank">23835436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17156356">
<a name="17156356"></a>Co-Minh HB, Demoly P, Guillot B, et al. Anaphylactic shock After Oral Intake and Contact Urticaria Due to Polyethylene Glycols. <i>Allergy</i>. 2007;62(1):92-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/17156356/pubmed" id="17156356" target="_blank">17156356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DiPalma.1">
<a name="DiPalma.1"></a>Di Palma JA. Braintree polyethylene glycol (PEG) laxative for ambulatory and long-term care facility constipation patients: report of randomized, cross-over trials. 1999. http://web.archive.org/web/20011216021050/http:/www.ojdh.org:80/current.dir/dipalma_braintree.html#top. Accessed August 31, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17984738">
<a name="17984738"></a>Di Palma JA, Cleveland MB, McGowan J, Herrera JL. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. <i>South Med J</i>. 2007a;100(11):1085-1090.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/17984738/pubmed" id="17984738" target="_blank">17984738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17311603">
<a name="17311603"></a>Di Palma JA, Cleveland MV, McGowan J, Herrera JL. An open-label study of chronic polyethylene glycol laxative use in chronic constipation. <i>Aliment Pharmacol Ther</i>. 2007b;25(6):703-708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/17311603/pubmed" id="17311603" target="_blank">17311603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17573794">
<a name="17573794"></a>Di Palma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. <i>Am J Gastroenterol</i>. 2007c;102(9):1964-1971. doi:10.1111/j.1572-0241.2007.01365.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/17573794/pubmed" id="17573794" target="_blank">17573794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17403074">
<a name="17403074"></a>Di Palma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation.<i> Am J Gastroenterol.</i> 2007d;102(7):1436-1441. doi:10.1111/j.1572-0241.2007.01199.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/17403074/pubmed" id="17403074" target="_blank">17403074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). Drug safety Oversight Board Meeting, June 18, 2019. Available at <a href="http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm171059.htm%20" target="_blank">http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm171059.htm</a>. Last accessed January 20, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). Potential signals of serious risks/new safety information identified by the Adverse Event Reporting System (AERS) between october - december 2011. Available at <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm295585.htm" target="_blank">http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm295585.htm</a> Last accessed January 20, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GaviLAX.1">
<a name="GaviLAX.1"></a>GaviLAX (polyethylene glycol 3350) [prescribing information]. Somerset, NJ: Gavis Pharmaceuticals; June 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29991883">
<a name="29991883"></a>Gomes CF, Sousa M, Lourenço I, Martins D, Torres J. Gastrointestinal diseases during pregnancy: what does the gastroenterologist need to know? <i>Ann Gastroenterol</i>. 2018;31(4):385‐394. doi:10.20524/aog.2018.0264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/29991883/pubmed" id="29991883" target="_blank">29991883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22732876">
<a name="22732876"></a>Gurudu SR, Ramirez FC, Harrison ME, Leighton JA, Crowell MD. Increased adenoma detection rate with system-wide implementation of a split-dose preparation for colonoscopy. <i>Gastrointest Endosc</i>. 2012;76(3):603-608.e1. doi:10.1016/j.gie.2012.04.456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/22732876/pubmed" id="22732876" target="_blank">22732876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33315591">
<a name="33315591"></a>Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. <i>Am J Gastroenterol</i>. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/33315591/pubmed" id="33315591" target="_blank">33315591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25691849">
<a name="25691849"></a>Lee SH, Cha JM, Lee JI, et al. Anaphylactic shock caused by ingestion of polyethylene glycol. <i>Intest Res</i>. 2015;13(1):90-94. doi:10.5217/ir.2015.13.1.90<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/25691849/pubmed" id="25691849" target="_blank">25691849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27550498">
<a name="27550498"></a>Lee SH, Hwang SH, Park JS, Park HS, Shin YS. Anaphylaxis to polyethylene glycol (Colyte®) in a patient with diverticulitis. <i>J Korean Med Sci</i>. 2016;31(10):1662-1663. doi:10.3346/jkms.2016.31.10.1662<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/27550498/pubmed" id="27550498" target="_blank">27550498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15572895">
<a name="15572895"></a>Loening-Baucke V, Krishna R, and Pashankar DS. Polyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlers. <i>J Pediatr Gastroenterol Nutr</i>. 2004;39(5):536-539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/15572895/pubmed" id="15572895" target="_blank">15572895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22711499">
<a name="22711499"></a>McKenna T, Macgill A, Porat G, Friedenberg FK. Colonoscopy preparation: polyethylene glycol with Gatorade is as safe and efficacious as four liters of polyethylene glycol with balanced electrolytes. <i>Dig Dis Sci</i>. 2012;57(12):3098-3105. doi:10.1007/s10620-012-2266-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/22711499/pubmed" id="22711499" target="_blank">22711499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32377915">
<a name="32377915"></a>Millien VO, Mansour NM. Bowel preparation for colonoscopy in 2020: a look at the past, present, and future. <i>Curr Gastroenterol Rep</i>. 2020;22(6):28. doi:10.1007/s11894-020-00764-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/32377915/pubmed" id="32377915" target="_blank">32377915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MiraLAX.1">
<a name="MiraLAX.1"></a>MiraLAX (polyethylene glycol 3350) [product information]. Whitehouse Station, NJ: Schering-Plough; August 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MiraLAX.4">
<a name="MiraLAX.4"></a>MiraLAX powder for solution (polyethylene glycol 3350) [prescribing information]. Berlin, Germany: Bayer; November 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MiraLAX.2">
<a name="MiraLAX.2"></a>MiraLAX powder for solution (polyethylene glycol 3350) [prescribing information]. Braintree, MA: Braintree Laboratories, Inc; 1999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MiraLAX.3">
<a name="MiraLAX.3"></a>MiraLAX powder for solution (polyethylene glycol 3350) [prescribing information]. Memphis TN: MSD Consumer Care, Inc; August 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11562624">
<a name="11562624"></a>Pashankar DS, Bishop WP. Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children. <i>J Pediatr</i>. 2001;139(3):428-432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/11562624/pubmed" id="11562624" target="_blank">11562624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15001943">
<a name="15001943"></a>Pashankar DS, Uc A, Bishop WP. Polyethylene glycol 3350 without electrolytes: a new safe, effective, and palatable bowel preparation for colonoscopy in children.<i> J Pediatr.</i> 2004;144(3):358-362. doi:10.1016/j.jpeds.2003.11.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/15001943/pubmed" id="15001943" target="_blank">15001943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18462266">
<a name="18462266"></a>Pelham RW, Nix LC, Chavira RE, et al. Clinical Trial: Single- and Multiple-Dose Pharmacokinetics of Polyethylene Glycol (PEG-3350) in Healthy Young and Elderly Subjects. <i>Aliment Pharmaco Ther</i>. 2008;28(2):256-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/18462266/pubmed" id="18462266" target="_blank">18462266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kremers.1">
<a name="Kremers.1"></a>Polyethylene Glycol 3350 [prescribing information]. Princeton, NJ: Kremers Urban Pharmaceuticals; August 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Relaxa.1">
<a name="Relaxa.1"></a>Relaxa (polyethylene glycol 3350) [product information]. Mississauga, Ontario, Canada: Red Leaf Medical; March 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23204909">
<a name="23204909"></a>Rowan-Legg A; Canadian Paediatric Society, Community Paediatrics Committee. Managing functional constipation in children. <i>Paediatr Child Health</i>. 2011;16(10):661-670.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/23204909/pubmed" id="23204909" target="_blank">23204909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22565162">
<a name="22565162"></a>Samarasena JB, Muthusamy VR, Jamal MM. Split-dosed MiraLAX/Gatorade is an effective, safe, and tolerable option for bowel preparation in low-risk patients: a randomized controlled study. <i>Am J Gastroenterol</i>. 2012;107(7):1036-1042. doi:10.1038/ajg.2012.115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/22565162/pubmed" id="22565162" target="_blank">22565162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30256031">
<a name="30256031"></a>Sari Gökay S, Çelik T, Yusuf Sari M, Ekinci F, Dinçer Yildizdaş R, Levent Yilmaz H. Urticaria as a rare side effect of polyethylene glycol-3350 in a child: case report. <i>Acta Clin Croat</i>. 2018;57(1):187-189. doi:10.20471/acc.2018.57.01.26<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/30256031/pubmed" id="30256031" target="_blank">30256031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25803402">
<a name="25803402"></a>Shin GH, Toto EL, Schey R. Pregnancy and postpartum bowel changes: constipation and fecal incontinence. <i>Am J Gastroenterol</i>. 2015;110(4):521‐530. doi:10.1038/ajg.2015.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/25803402/pubmed" id="25803402" target="_blank">25803402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30557713">
<a name="30557713"></a>Stone CA Jr, Liu Y, Relling MV, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. <i>J Allergy Clin Immunol Pract</i>. 2019;7(5):1533-1540.e8. doi:10.1016/j.jaip.2018.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/30557713/pubmed" id="30557713" target="_blank">30557713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24345831">
<a name="24345831"></a>Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. <i>J Pediatr Gastroenterol Nutr</i>. 2014;58(2):258-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/24345831/pubmed" id="24345831" target="_blank">24345831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wald.1">
<a name="Wald.1"></a>Wald A. Management of chronic constipation in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16741637">
<a name="16741637"></a>Wexner SD, Beck DE, Baron TH, et al. A Consensus Document on Bowel Preparation Before Colonoscopy: Prepared by a Task Force from The American Society of Colon and Rectal Surgeons (ASCRS), The American Society for Gastrointestinal and Endoscopy (ASGE) and The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). <i>Dis Colon Rectum</i>. 2006;49(6):792-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/16741637/pubmed" id="16741637" target="_blank">16741637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12219064">
<a name="12219064"></a>Youssef NN, Peters JM, Henderson W, et al. Dose response of PEG 3350 for the treatment of childhood fecal impaction.<i> J Pediatr.</i> 2002;141(3):410-414. doi:10.1067/mpd.2002.126603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/12219064/pubmed" id="12219064" target="_blank">12219064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30865011">
<a name="30865011"></a>Zawaly K, Rumbolt C, Abou-Setta AM, et al. The efficacy of split-dose bowel preparations for polyp detection: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2019;114(6):884-892. doi:10.14309/ajg.0000000000000155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/30865011/pubmed" id="30865011" target="_blank">30865011</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10231 Version 430.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
